Financing will support i20 Therapeutics’ growth and R&D of platform for oral delivery of injectable biologic drugs BOSTON, April 9, 2020-- i2O Therapeutics, an innovative biotech company developing a platform for oral delivery of traditionally injectable biological drugs, announced today it has raised a $4 million seed funding round led by Sanofi Ventures and JDRF T1D Fund. Founded by a team of researchers from Harvard University, i2O Therapeutics is focused on the development of safe and effective oral formulations of therapies that are conventionally limited to injections, e.g. biologics, large molecules, and peptide-based pharmaceuticals such as insulin.